Lupin Manufacturing Solutions

Lupin Manufacturing Solutions company information, Employees & Contact Information

Lupin Manufacturing Solutions (LMS), a wholly owned subsidiary of Lupin, specializes in delivering high-quality APIs and comprehensive CDMO services to accelerate drug development from bench to market. Backed by Lupinโ€™s five decades of pharmaceutical expertise, LMS provides cost-effective, integrated solutions tailored to client needs. From R&D and process development to clinical manufacturing, large-scale production, and regulatory support, we offer end-to-end services that ensure seamless drug development and delivery. ๐ƒ๐ซ๐ฎ๐  ๐’๐ฎ๐›๐ฌ๐ญ๐š๐ง๐œ๐ž Our strong legacy in API manufacturing and vertically integrated operations ensure uncompromising quality and cost efficiency. Since we are based in India, our manufacturing costs are significantly lower, enabling us to pass significant cost benefits to our clients. Sustainable practices are adopted throughout our value chain giving clients the advantage of reducing the impact of operations on the environment. ๐ˆ๐ง๐ญ๐ž๐ ๐ซ๐š๐ญ๐ž๐ ๐Ž๐Ÿ๐Ÿ๐ž๐ซ๐ข๐ง๐  Our R&D, Manufacturing, Quality, and Regulatory teams excel in diverse disciplines and have deep industry experience. This enables us to offer end-to-end product development, scale and commercialization, with a proven track record of securing regulatory approvals globally. Our world-class manufacturing facilities in Dabhasa and Vizag, a state-of-the-art R&D center in Pune, and a team with deep expertise position us as the partner of choice for API and CDMO solutions.

Company Details

Employees
274
Founded
-
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Looking for a particular Lupin Manufacturing Solutions employee's phone or email?

Lupin Manufacturing Solutions Questions

News

Lupin Launches Bumetanide Injection, USP in the United States - lupin.com

Lupin Launches Bumetanide Injection, USP in the United States lupin.com

Governor Murphy and Local Leaders Attend Ribbon-Cutting Ceremony, Marking the Inauguration of Lupin's New Corporate Offices in Bridgewater - The Malaysian Reserve

Governor Murphy and Local Leaders Attend Ribbon-Cutting Ceremony, Marking the Inauguration of Lupin's New Corporate Offices in Bridgewater The Malaysian Reserve

Lupin Announces Plans to Build a New State-of-the-Art Manufacturing Facility in Coral Springs, Florida Extending its Long-Standing Commitment to America's Patients and Healthcare System - PR Newswire

Lupin Announces Plans to Build a New State-of-the-Art Manufacturing Facility in Coral Springs, Florida Extending its Long-Standing Commitment to America's Patients and Healthcare System PR Newswire

Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025 - Eastern Progress

Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025 Eastern Progress

GHO Capital Sells VISUfarma to Lupin - GlobeNewswire

GHO Capital Sells VISUfarma to Lupin GlobeNewswire

Lupin receives FDA approval for Loteprednol Etabonate Ophthalmic Gel, 0.38% - Ophthalmology Times

Lupin receives FDA approval for Loteprednol Etabonate Ophthalmic Gel, 0.38% Ophthalmology Times

Lupin Receives U.S. FDA Approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity, the First Product from its Nanomi's Long-Acting Injectable Platform - Morningstar

Lupin Receives U.S. FDA Approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity, the First Product from its Nanomi's Long-Acting Injectable Platform Morningstar

Lupin Unveils Strategic Partnership Program to Expand Reach of its Long-Acting Injectable Platform - Lelezard

Lupin Unveils Strategic Partnership Program to Expand Reach of its Long-Acting Injectable Platform Lelezard

FDA Approves Lupinโ€™s Generic Tolvaptan Tablets - Docwire News

FDA Approves Lupinโ€™s Generic Tolvaptan Tablets Docwire News

Lupin Secures a Place in the Prestigious S&P Global Sustainability Yearbook 2025 - lupin.com

Lupin Secures a Place in the Prestigious S&P Global Sustainability Yearbook 2025 lupin.com

Sandoz will license Lupin's ranibizumab biosimilar in Europe, other select regions - Ophthalmology Times Europe

Sandoz will license Lupin's ranibizumab biosimilar in Europe, other select regions Ophthalmology Times Europe

Lupin Receives EIR from U.S. FDA for its Pithampur Unit-1 Facility with VAI Classification - lupin.com

Lupin Receives EIR from U.S. FDA for its Pithampur Unit-1 Facility with VAI Classification lupin.com

Lupin Q1 FY2026 Results - lupin.com

Lupin Q1 FY2026 Results lupin.com

Lupin and Honeywell Move Forward Jointly with Plans for HFO Technology in Inhalers - PR Newswire

Lupin and Honeywell Move Forward Jointly with Plans for HFO Technology in Inhalers PR Newswire

Lupin Announces Presentation of Phase 1 Data on LNP7457 (PRMT5 inhibitor) at the American Society of Clinical Oncology - Annual Meeting 2025 - PR Newswire

Lupin Announces Presentation of Phase 1 Data on LNP7457 (PRMT5 inhibitor) at the American Society of Clinical Oncology - Annual Meeting 2025 PR Newswire

Lupin Announces the Acquisition of Renascience in the United Kingdom - Business Wire

Lupin Announces the Acquisition of Renascience in the United Kingdom Business Wire

Lupinโ€™s ESG Score Rises to 76 in S&P Global ESG Ratings - lupin.com

Lupinโ€™s ESG Score Rises to 76 in S&P Global ESG Ratings lupin.com

Lupin and Avas Launch NaMusclaยฎ in Italy - GlobeNewswire

Lupin and Avas Launch NaMusclaยฎ in Italy GlobeNewswire

Leading Pharmaceutical Company in the US - lupin.com

Leading Pharmaceutical Company in the US lupin.com

Our Products and Offerings - lupin.com

Our Products and Offerings lupin.com

Lupin Divests U.S. Commercial Women's Health Specialty Business to Evofem, including SOLOSEC - PR Newswire

Lupin Divests U.S. Commercial Women's Health Specialty Business to Evofem, including SOLOSEC PR Newswire

Key Therapeutic Areas - lupin.com

Key Therapeutic Areas lupin.com

Unclaimed Dividend - lupin.com

Unclaimed Dividend lupin.com

Our Story | About Us - lupin.com

Our Story | About Us lupin.com

Research and Development (R&D) - lupin.com

Research and Development (R&D) lupin.com

Accenture Accelerates Data-Driven Decision Making for Lupin - Accenture

Accenture Accelerates Data-Driven Decision Making for Lupin Accenture

Lupinโ€™s R&D Facility in Pune Awarded LEED Platinum Certification - Business Wire India

Lupinโ€™s R&D Facility in Pune Awarded LEED Platinum Certification Business Wire India

Lupin Selects Hewlett Packard Enterprise to Accelerate Innovation and Optimize Cloud Costs - Business Wire

Lupin Selects Hewlett Packard Enterprise to Accelerate Innovation and Optimize Cloud Costs Business Wire

Shareholding Pattern - lupin.com

Shareholding Pattern lupin.com

Lupin Q4 FY2024 Results - lupin.com

Lupin Q4 FY2024 Results lupin.com

Committees of the Board - lupin.com

Committees of the Board lupin.com

Netflix Today Confirms Original French Series 'Lupin' Will Return Summer 2021 - About Netflix

Netflix Today Confirms Original French Series 'Lupin' Will Return Summer 2021 About Netflix

Lupin Announces Partnership with Phil, Inc. in Support of SOLOSECยฎ (secnidazole) - PR Newswire

Lupin Announces Partnership with Phil, Inc. in Support of SOLOSECยฎ (secnidazole) PR Newswire

Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada - Stock Titan

Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada Stock Titan

Lupin Pharmaceuticals and PlushCare Expand Access to Bacterial Vaginosis (BV) Treatment to Help Meet Patient Needs During COVID-19 Pandemic - PR Newswire

Lupin Pharmaceuticals and PlushCare Expand Access to Bacterial Vaginosis (BV) Treatment to Help Meet Patient Needs During COVID-19 Pandemic PR Newswire

Mylan and Lupin Receive European Marketing Authorization for Nepextoยฎ, Biosimilar Etanercept - PR Newswire

Mylan and Lupin Receive European Marketing Authorization for Nepextoยฎ, Biosimilar Etanercept PR Newswire

Top five generic drug makers - European Pharmaceutical Review

Top five generic drug makers European Pharmaceutical Review

Lupin Announces Opening of its new 100,000 square foot expansion at its Somerset, NJ Manufacturing Site - PR Newswire

Lupin Announces Opening of its new 100,000 square foot expansion at its Somerset, NJ Manufacturing Site PR Newswire

Lupin and Mylan Partner to Commercialize Enbrelยฎ (Etanercept) Biosimilar - PR Newswire

Lupin and Mylan Partner to Commercialize Enbrelยฎ (Etanercept) Biosimilar PR Newswire

Lupin receives UK marketing authorisation for Luforbecยฎ 100/6 pMDI, first branded generic alternative to Fostairยฎ to treat Asthma & COPD - PharmiWeb.com

Lupin receives UK marketing authorisation for Luforbecยฎ 100/6 pMDI, first branded generic alternative to Fostairยฎ to treat Asthma & COPD PharmiWeb.com

Lupin Announces Health Canada Approval of Tiotropium Bromide Inhalation Powder for Treatment of COPD - PR Newswire Canada

Lupin Announces Health Canada Approval of Tiotropium Bromide Inhalation Powder for Treatment of COPD PR Newswire Canada

Lupin launches HIV drugs in US - BioSpectrum India

Lupin launches HIV drugs in US BioSpectrum India

Lupin Launches First-ever Duloxetine 40mg Delayed-Release Capsules in the US - PR Newswire

Lupin Launches First-ever Duloxetine 40mg Delayed-Release Capsules in the US PR Newswire

Lupin Launches New Generic Cymbalta Strength - Medical Professionals Reference

Lupin Launches New Generic Cymbalta Strength Medical Professionals Reference

Arsรจne Lupin (2004) โญ 5.4 | Action, Adventure, Crime - IMDb

Arsรจne Lupin (2004) โญ 5.4 | Action, Adventure, Crime IMDb

Lupin Share Price Target 2025, 2026, 2030, 2040, 2050 - shareprice-target.com

Lupin Share Price Target 2025, 2026, 2030, 2040, 2050 shareprice-target.com

Top Lupin Manufacturing Solutions Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant